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A B S T R A C T   
Lipid-based vesicles have found widespread applications in the life sciences, allowing for fundamental insights into 
membrane-based processes in cell biology and as carrier systems for drug delivery purposes. So far, mostly small 
unilamellar vesicles (SUVs) with diameters of ~100 nm have been applied as carrier systems for biomedical 
applications. Despite this progress, several systematic limitations have arisen due to SUV dimensions, e.g., the size 
and total amount of applicable cargo is limited. Giant unilamellar vesicles (GUVs) might offer a pragmatic al-
ternative for efficient cargo delivery. However, due to the lack of reliable high-throughput production technologies 
for GUV-carrier systems, only little is known about their interaction with cells. Here we present a microfluidic- 
based mechanical droplet-splitting pipeline for the production of carrier-GUVs with diameters of ~2 μm. The 
technology developed allows for highly efficient cargo loading and unprecedented control over the biological and 
physicochemical properties of GUV membranes. By generating differently charged (between −31 and + 28 mV), 
bioligand-conjugated (e.g. with E-cadherin, NrCam and antibodies) and PEG-conjugated GUVs, we performed a 
detailed investigation of attractive and repulsive GUV-cell interactions. Fine-tuning of these interactions allowed 
for targeted cellular GUV delivery. Moreover, we evaluated strategies for intracellular GUV cargo release by ly-
sosomal escape mediated by the pH sensitive lipid DOBAQ, enabling cytoplasmic transmission. The presented GUV 
delivery technology and the systematic characterization of associated GUV-cell interactions could provide a means 
for more efficient drug administration and will pave the way for hitherto impossible approaches towards a targeted 
delivery of advanced cargo such as microparticles, viruses or macromolecular DNA-robots.   
1. Introduction 
Lipid-based SUVs, with diameters ~100 nm, have been extensively 
studied as transport systems in the food, cosmetic and pharmaceutical 
industries. Particularly, they have been implemented to serve as na-
nosensors for monitoring food quality during storage [1], as vehicles for 
the transdermal delivery of cosmetic agents [2], or as carrier systems 
for targeted drug therapy [3]. Such liposomal delivery systems offer 
improved control over drug pharmacokinetics and pharmacodynamics 
[4], provide the potential to decrease toxicity and adverse side effects 
[5], enhance targeted delivery to specific tissues [6] and increase 
compound circulation times [5]. 
Despite the beneficial impact of SUV-based delivery systems, the road 
towards their broad applicability remains complex. The major challenges 
that are currently faced fall into two broad categories. First, the total 
amount of pharmaceutically active compounds that can be entrapped in 
a single liposome is meager, potentially not reaching the desired ther-
apeutic dose at its destination [7]. Second, entrapment efficiency into 
liposomes is usually very low (around 10% for water-soluble com-
pounds) and active loading approaches are complex, expensive and time 
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consuming [8,9]. Moreover, large cargos are expected to be part of future 
therapeutic approaches, including nanoparticles or supramolecular DNA 
and RNA complexes. For instance, DNA origami complexes have been 
proposed to enhance chemotherapies and fluorescent semiconductor 
nanocrystals (nano dots) have proven to improve in vivo imaging ap-
proaches [10,11]. Loading such large cargo into small liposomes is ex-
tremely challenging if not impossible. GUVs, in contrast, with radii ex-
ceeding 1 μm might thus offer great potential for drug delivery 
applications, as they can carry much larger quantities of active com-
pounds as well as particles up to several micrometers in size [12,13]. 
With the recent rise of bottom-up synthetic biology, GUVs have 
seen a science community-wide surge in popularity for other uses as 
well. In this context, GUV-based compartments have been designed to 
recreate the essential characteristics of life as described by the 
Chemoton model [14]. This gave rise to several microfluidic GUV 
production techniques like double emulsion methods [15], octanol 
assisted liposome assembly [16], microfluidic multicompartment 
synthetic cells [17] and multi-module devices for microfluidic hand-
ling of GUVs [18]. Research in this area is currently focused on the 
construction of synthetic cellular constituents and artificial cells 
which serve as biomimetic systems that incorporate cell-like struc-
tures and exhibit cell-like behavior [19]. In addition to the attention 
on fully synthetic cell systems, a special focus has also been laid on 
hybrid systems, which are used to investigate interactions between 
synthetic cell-like GUVs with living cells [20]. 
Despite the growing demand for GUV-based biomedical and synthetic 
biology applications, the potential of GUVs to deliver large and complex 
cargos into the intracellular space or, in general, their ability to interact 
with living cells have been only superficially explored to date [21]. In 
this study, we characterized physical, chemical and biological key 
parameters that conquer the interactions between living cells and GUVs. 
Towards this end, we implemented the recently developed droplet-based 
microfluidic method for high-throughput production of large, surfactant- 
free GUV quantities with exquisite entrapment efficiencies of small mo-
lecules and micrometer-sized particles [22,23,54]. This production 
method for droplet-stabilized GUVs (dsGUVs) offers a high level of 
control over lipid and luminal composition (see Supplementary Note 1) 
as well as a large spectrum of compatible buffer compositions, rendering 
it an attractive technology for the controlled synthesis of GUVs with 
tunable properties for drug delivery and synthetic biology studies 
[19,24]. Using this technology, we here provide a first comprehensive 
and thorough analysis of GUV-cell interactions and present a concept for 
targeted GUV-mediated delivery into cells. 
2. Results and discussion 
2.1. Microfluidic mechanical splitting of droplet-stabilized GUVs 
Assembling GUVs from SUV precursors within microfluidic water-in- 
oil (w/o) droplet architectures offers excellent control over GUV com-
position as well as high production rates [23]. This approach has pre-
viously been used to produce cell-sized or even larger GUVs with dia-
meters of ~50 μm, which have served as durable, excellent to handle and 
low-cost mimics of living cells as their unilamellar membrane closely 
resembles a cellular membrane [22–24]. However, GUVs identical or 
larger in size than typical cells are of limited use for intracellular delivery 
strategies (see Figure S1). Downsizing droplets to produce GUV sizes 
smaller than 5 μm using flow focusing junctions requires sophisticated 
lithography procedures and complex channel architectures, measures 
that restrict reliable high-throughput small-droplet production [25,26]. 
To overcome these technological limitations, we designed a droplet- 
based microfluidic device consisting of a flow focusing junction for w/o- 
droplet production and a multi-V-shaped microfluidic droplet splitting 
unit (Fig. 1a, Figure S2). Similar microfluidic designs have previously 
been described for high throughput droplet-splitting [27,28]. Following 
production of 60 μm diameter droplets (See Experimental Section), this 
design allows for high-throughput mechanical droplet splitting in up to 
five consecutive division steps, thereby creating droplets with a final 
diameter of 2.90 μm  ±  0.45 μm (n = 202) (Video S1). 
Supplementary data related to this article can be found at https:// 
doi.org/10.1016/j.biomaterials.2020.120203. 
To assess transmission heterogeneity of intraluminal contents from 
the mother to the daughter droplets, we performed fluorescence confocal 
microscopy analysis of fluorescent droplet content and analyzed re-
spective signal intensity distributions among droplets before and after 
splitting (Fig. 1b). The results revealed only marginal interdroplet 
variation of signal intensity for the low molecular weight fluorophore 
AlexaFluor 405 before splitting (Coefficient of variation 
(CV) before = 5.6%, n = 29) and after splitting (CVafter = 10.7%, 
n = 665), green fluorescent protein (CVbefore = 18.5%, n = 29 and 
CVafter = 14.8%, n = 665) and 100 nm fluorescently labeled SUVs 
composed of 20 mol% EggPG, 79 mol% EggPC and 1 mol% LissRhod PE 
Fig. 1. Microfluidic formation of GUVs and their interactions with living cells. (a) Phase-contrast microscopy image showing the microfluidic device used for serial 
five-fold mechanical dsGUV division, resulting in the formation of 32 daughter droplets from a single 60 μm droplet. The inset shows a higher magnification of the 
mechanical division of a droplet at a V-junction over a time course of 16 msec. The scale bars are 300 μm (left) and 60 μm (right). (b) Single plane fluorescence 
confocal microscopy images of mechanically split droplets loaded with AlexaFluor 405 (blue), fluorescently labeled SUVs (1 mol% LissRhod PE, yellow), green 
fluorescent protein (green) and 1 μm fluorescent polystyrene beads (purple). Upper right corner indicates CV of the droplet mean signal intensity (n = 665 single 
droplets). The scale bar is 40 μm. (c) Single plane fluorescence confocal microscopy images of split GUVs (20 mol% EggPG, 79 mol% EggPC and 1 mol% LissRhod PE) 
released in PBS. The scale bar is 25 μm. (d) Representative phase contrast image of mechanically split GUVs incubated with rat embryonic fibroblasts. White arrows 
indicate single GUVs. The scale bar is 10 μm. See Table S1 for details on the lipid and buffer compositions. 
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(CVbefore = 68.0%, n = 29 and CVafter = 15.4%, n = 665). Only 1 μm 
polystyrene beads showed asymmetric distribution after mechanical di-
vision, presumably because their size and concentration only allows for 
Bernoulli-like splitting distributions. Based on this, we concluded that the 
luminal composition of split droplets mostly resembles the composition 
of the mother droplets. Thus, our mechanical splitting approach is sui-
table for the controlled production of small w/o-droplets with defined 
and tunable compositions at high production rates (e.g., 2.5 × 105 and 
8 × 106 droplets/min at the focusing T-junction and after serially 
splitting the droplet five times, respectively). Importantly, we found 
peripheral distribution of lipid fluorescence in the divided droplets, 
suggesting the successful mechanical division of dsGUVs. Indeed, fol-
lowing the addition of destabilizing surfactant to the dsGUVs collected 
from mechanically split droplets (see Experimental Section), we were 
able to release large quantities of GUVs (diameter = 1.400 μm  ±  
0.202 μm, n = 122) into an aqueous phase (Fig. 1c). Note, 1.5 mM was 
found to be the optimal SUV concentration, achieving over 50% GUV 
release efficiency, corresponding to a successful release from approxi-
mately every second droplet (Fig. S3a). Under optimized conditions this 
method allows for a GUV production rate of approximately 4 × 106 
GUVs/min. 
Full control over the physicochemical and biological properties of 
GUVs is a pivotal requirement for biomedical and synthetic biology ap-
plications. Therefore, we applied mass spectrometry (see Experimental 
Section) to quantitatively assess the lipid composition of the formed 
GUVs. The results revealed that the GUV lipid ratio resembles the lipid 
ratio used during dsGUV production, thus indicating that the lipid ratio is 
unaffected by microfluidic handling and mechanical droplet splitting 
(Fig. S3b). Additionally, we performed a basic assessment of the me-
chanical stability of the formed GUVs and found that approximately 90% 
of the GUVs tolerate incubation at 37 °C and mechanical agitation on a 
horizontal shaker at 800 rpm for 24 h. This shows that released droplet- 
splitted GUVs are stable under agitation in a time frame required for 
most liposomal drug delivery applications [29] (Fig. S3c). 
To successfully interface GUVs with living cells, it is critical to 
produce and maintain GUVs under physiological buffer conditions. 
Therefore, we systematically assessed the release efficiency of me-
chanically split GUVs filled with serum-supplemented cell culture 
medium. Similarly, to production with PBS and water, we obtained up 
to 45% release efficiency in cell culture medium (Fig. S3d). Following 
release, GUVs were incubated with rat embryonic fibroblasts (REF) in 
cell culture. Importantly, time-lapse microscopy analysis showed that 
these GUVs remained stable over a period of at least 20 h incubation 
(Fig. 1d and Video S2). 
Supplementary data related to this article can be found at https:// 
doi.org/10.1016/j.biomaterials.2020.120203. 
2.2. Charge-mediated GUV- cell interactions 
Charge-mediated interactions between liposomes and cells have been 
extensively studied for small vesicles (< 100 nm). These studies have 
pinpointed major factors that conquer the cell-vesicle interplay. 
Potentially, if precisely controlled, charge-mediated interactions might 
serve as a potent instrument to also guide the interactions between cells 
and GUVs. Therefore, we systematically investigated the interaction 
spectrum of differently charged mechanically split GUVs incubated with 
various cell lines in vitro. To this end, we employed mechanical splitting 
to produce GUVs with varying amounts of positively (DOTAP) and ne-
gatively (DOPG) charged lipids and measured their respective ζ-potential 
using dynamic light scattering (Table 1). We found that by altering the 
respective lipid amounts, the charge of the GUVs can be adjusted ranging 
from highly positive to highly negative charged vesicles. 
To quantify the interactions between cells and GUVs, we implemented 
a plate reader-based attraction assay (Fig. S4) and interfaced cell lines of 
endothelial (MDCK), epithelial (A431D and A431) and adrenal (PC12) 
origin with respective GUVs. These cell lines were selected in order to 
cover a wide spectrum of possible target tissues with different surface 
patterns. We found a strong correlation between GUV charge and cell 
attraction for all tested cell lines, showing that any increase in charge 
results in a greater GUV attraction; non-charged GUVs displayed the least 
cell attraction (Fig. 2a). For example, in the case of A431D cells, a fre-
quently used model cell line in carcinoma research, GUVs with a ζ-po-
tential of −31 mV showed almost 100 times stronger attraction than 
GUVs with +2 mV ζ-potential. Inversely, GUVs with a ζ-potential of 
+28 mV had 50 times greater attraction than GUVs with +2 mV ζ-po-
tential. However, this quantitative assay is not able to discriminate be-
tween different types of interactions (e.g., uptake, attachment, fusion or 
engulfment). Therefore, we investigated the qualitative nature of the GUV- 
cell interactions with fluorescence confocal microscopy. As shown in  
Fig. 2b, we were able to discriminate between three distinct types of GUV- 
A431D cell interactions: endocytosis, attachment and fusion. We also 
found the different types of cell interactions to be distinctly associated 
with specific states of charge – endocytosis is primarily observed on ne-
gatively charged GUVs, attachment with neutral GUVs and fusion with 
positively charges GUVs. Fusion was evident when lipid fluorescence co- 
localized with cell membrane staining (in many cases accompanied by 
morbid cell morphologies). To confirm that negatively charged GUVs are 
indeed taken up by the cells, we performed two additional analyses: First, 
we stained the cell's cytoplasm and performed z-resolved confocal fluor-
escence microscopy of internalized fluorescently labeled GUVs (Video S3). 
Second, we fixed the cells that have been incubated with respective GUVs 
and performed transmission electron microscopy (Fig. S4). Both assess-
ments unequivocally proved that GUVs are indeed taken up by the cells 
and reside within their cytoplasm. Taken together, these results reveal the 
pervasive effects of GUV charge on GUV-cell interactions and highlight the 
value of developing methods for GUV charge control. 
Supplementary data related to this article can be found at https:// 
doi.org/10.1016/j.biomaterials.2020.120203. 
2.3. Biofunctionalization of GUVs formed by droplet splitting microfluidic 
device 
Despite the fact that charge-mediated cellular uptake of GUVs is an 
efficient process, it fails to provide a cell type-specific delivery of ther-
apeutic compounds. Therefore, we aimed to introduce additional ligand- 
directed guidance for GUV uptake by developing a toolbox of strategies 
for bio-orthogonal functionalization of the GUV surface with specific 
targeting biomolecules. To exemplarily demonstrate the diversity of GUV 
biofunctionalization possibilities, we produced GUVs by microfluidic 
droplet splitting harboring a combination of three linkers: biotinylated 
lipids for coupling to streptavidin tagged proteins, NTA-Ni2+-functio-
nalized lipids for coupling to histidine-tagged proteins, and DOPE lipids 
containing primary ammine for linking to N-hydroxysuccimid (NHS)- 
functionalized molecules. We achieved triple orthogonal functionaliza-
tion of the released GUVs by adding Atto425-labeled streptavidin, his-
tidine-tagged green fluorescent protein and NHS-functionalized 
Alexa647 (Fig. 3a). Moreover, we tested more complex sequential 
functionalization strategies. Towards this end, we immobilized cysteine- 
functionalized gold nanoparticles to the GUV lipids via NHS-chemistry 
(Fig. 3b and Video S4). Additionally, we tested a multistep approach to 
couple immunoglobulins (e.g. anti-CD3) via NTA-immobilized His-tagged 
protein G (Fig. 3c). Of note, this approach was focused on coupling 
Table 1 
ζ-potential values of the released GUVs that contained different lipid compo-
sitions and were created by microfluidic mechanical splitting of dsGUVs.        
Lipid Type Lipid ratio 
DOTAB (mol%) 0 0 0 20 50 
DOPC (mol%) 49 79 99 79 49 
DOPG (mol%) 50 20 0 0 0 
LissRhod PE (mol%) 1 1 1 1 1 
ζ-potential (mV) −31 −19 +2 +20 +28 
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ligands of interest to the outer GUV leaflet. However, since the functional 
groups conjugated to the lipids are also exposed on the inner GUV leaflet, 
intraluminal coupling could also be explored in future studies. 
Supplementary data related to this article can be found at https:// 
doi.org/10.1016/j.biomaterials.2020.120203. 
Notably, antibodies offer great selectivity for particular cell surface an-
tigens, which is why antibody-based targeting has previously been shown to 
greatly enhance specific SUV delivery to defined cell subsets [30]. To assess 
the functionality of anti-CD3-coated GUVs, we incubated them with CD3+ 
Jurkat cells (see Experimental Section). When analyzed by confocal micro-
scopy, the formation of an attachment site between the GUVs and the cells, 
strikingly reminiscent of a “minimal” immunological synapse, was observed 
(Fig. 3d), indicating successful GUV-cell coupling. In contrast, GUVs without 
anti-CD3 coating did not show this complex interaction architecture. 
To systematically assess the possibility of employing attractive, receptor- 
specific GUV-cell interactions for targeted GUV delivery, we produced ne-
gatively charged and RGD-biofunctionalized GUVs with varying ligand 
densities (Fig. 3e). We decided to use the RGD tripeptide for GUV bio-
functionalization as integrin receptor-based endocytosis has previously been 
shown to enhance liposomal drug delivery due to the ability of integrin 
proteins to function as natural intracellular signal transducers for the 
initiation of endocytic events [31]. Therefore, we interfaced RGD-GUVs with 
adherent cell lines expressing RGD-binding integrin receptors and measured 
their attraction. As a control we incubated the same cells with non-functio-
nalized, naive GUVs. For all cell lines tested (Fig. 3f), we found that RGD 
ligand density on the cell periphery correlates with GUV attraction. In ad-
dition, GUV-cell coupling can be increased by approximately 10% when 
applying 10 mol%-RGD ligand decoration. In the case of non-adherent 
Jurkat T-cells, that express high levels of α4β1 integrin [32], 10 mol%-RGD 
coating increased GUV-cell coupling even 15-fold (as measured by fluores-
cence flow cytometry). We further analyzed the nature of the interaction 
between RGD-GUVs and cells by confocal microscopy. When interfaced with 
A431D cells, GUVs mostly accumulated at the cell periphery, the region with 
the highest integrin density, and in the perinuclear region, suggesting RGD- 
integrin-mediated endocytotic GUV uptake by the cells (Fig. 3g). 
2.4. Regulating attractive and repulsive GUV-cell interactions for targeted 
delivery 
Although biofunctionalization of GUVs with anti-CD3 and RGD li-
gands successfully increased GUV-cell interactions, charge-driven and 
other nonspecific attractions at the GUV-cell interface might still be 
Fig. 2. Charge-mediated GUV-cell interactions. (a) Attraction quantification of differently charged GUVs (ζ-potential as indicated on x-axis) with cell lines of 
endothelial (MDCK), epithelial (A431D and A431) and adrenal (PC12) origin after 24 h of joint incubation (results are shown as average values normalized to −31 
mV average and SD from three technical replicates). (b) Representative single plane fluorescence confocal microscopy images and schematic representation of 
charge-mediated GUV-A431D cell interactions after 24 h of joint incubation and several washing steps. Nuclei (first column) were stained with Hoechst 33342, cell 
membranes (second column) were stained with WGA-AlexaFluor488 and GUVs (third column) were visualized by incorporation of LissRhod-PE fluorescent lipids into 
GUVs. The respective GUV charge is indicated on the left side of the image. The scale bar is 20 μm. See Table S1 for details on the lipid and buffer compositions. 
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strong enough to interfere with ligand-based cell type-specific uptake. 
For example, when incubating non-charged GUVs functionalized with 
NrCAM proteins together with SH-SY5Y neuroblastoma cells, the 
measured attraction was comparable to that of non-functionalized, non- 
charged GUVs (Fig. S6). This indicates that the strength of nonspecific 
lipid-cell interactions is considerably high and can interfere greatly 
with ligand-based binding. Inspired by so-called “stealth” liposomes, 
which are commonly used for uptake studies using small vesicle 
(< 100 nm) [33], we set out to produce poly-ethylenglycol (PEG)- 
covered GUVs with the purpose of minimizing electrostatic and other 
non-specific interactions (Fig. 4a). Moreover, respective PEGylated 
vesicles are also known to exert reduced surface biofouling, providing 
increased interface stability and lower opsonin coating [34]. To char-
acterize the shielding potential of PEG on GUVs of different charges, we 
(caption on next page) 
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produced GUVs containing either 15 or 50 mol% negatively and posi-
tively charged lipids. We then tested a series of concentrations (5, 10, 
20 and 50 mol%) of lipids linked to PEG with different molecular 
weights (PEG350, PEG750 or PEG1000). Importantly, we did not ob-
serve any prominent difference in dsGUV formation when applying 
SUVs harboring PEG350 and PEG750 conjugated lipids. However, for 
SUVs containing 20 mol% and 50 mol% PEG1000 lipids, a reduced 
dsGUV formation was observed, probably due to charge-shielding ef-
fects between the PEGylated SUV surface and the droplet periphery. In 
a first step, we measured the ζ-potential of respective SUVs before 
dsGUV production and the ζ-potential of the released GUVs (Fig. S7a). 
The results reveal that the ζ-potential of both negatively and positively 
charged vesicles decreases with increasing length of the PEG chain and 
the rate of PEGylation. In a second step, we tested whether PEGylation 
of the GUVs and the associated masking of the GUV surface charge, 
results in the creation of a repulsive interaction between GUVs and 
cells. Towards this end, we incubated PEGylated GUVs with six dif-
ferent cell lines established from different tissues and measured the 
respective GUV attraction (Fig. S7b). The results revealed that for all 
tested cell lines, GUV PEGylation decreased charge-mediated attraction 
between the GUVs and the cells. Moreover, this effect was more pro-
nounced in cases of higher PEGylation rates and longer PEG length. For 
example, in the case of GUV interactions with A431D carcinoma cells, 
GUVs equipped with 5 mol% PEG350 showed almost 50% more at-
traction compared to GUVs equipped with 50 mol% PEG350 (Fig. 4b). 
Consistently, confocal microscopy analysis showed that naive, nega-
tively charged GUVs were usually localized within or above cells and 
only a small fraction was found between single cells or cell groups 
(Fig. 4c top panel). In contrast, PEGylated GUVs were observed mostly 
accumulating in the intercellular space, forming contact inhibition 
zones between accumulations of GUVs and individual cells (Fig. 4c 
bottom panel). Most probably, this behavior can be attributed to re-
pulsive GUV-cell interactions. 
With the ultimate goal of developing a fine-tuned means for tar-
geted uptake of GUVs into specific cells, we developed complementary 
strategies that decrease distorting, nonspecific, electrostatic attractive 
interactions between cells and GUVs through PEG-based passivation, 
and promote specific interactions through GUV biofunctionalization 
using cell type-specific ligands. 
To this end, we combined the strategies of PEGylation and bio-
functionalization of GUVs and completed a screen for cell type se-
lectivity. To achieve that, we produced GUVs consisting of 20 mol% 
negatively charged EggPG lipids, 54 mol% neutral EggPC lipids, 20 mol 
% PEG750-linked lipids, 5 mol% LissRhod PE and 1 mol% NHS-coupled 
lipids for ligand immobilization. In this lipid composition, the net 
strength of ligand-receptor interactions between the GUV and the target 
cell needs to be strong enough to overcome PEG-mediated repulsion, 
eventually allowing cell type-specific endocytosis induced by the ne-
gative GUV charge (Fig. 5a). To assess the specificity, we first screened 
15 types of differently functionalized GUVs, each of which we expected 
to be either specific for a given cell type (e.g. anti-cadherin antibodies 
or bradykinin) or nonspecific (e.g. poly-L-lysine) and measured re-
spective attraction values for six different carcinogenic cell lines. Re-
spective carcinogenic cells might resemble potentially interesting tar-
gets for GUV-based tumor treatment. In order to reference all attraction 
values for each cell type to a common, moderately unreactive protein, 
all values obtained were normalized to the attraction value determined 
for BSA-coupled GUVs (Fig. S8). Fig. 5b shows the attraction values 
between the six differently functionalized GUVs and six cell lines of 
different origin. GUVs coated with peptides and proteins which do not 
Fig. 3. Strategies for GUV biofunctionalization and receptor-specific GUV-cell interactions. (a) Schematic illustration and representative single plane fluorescence 
confocal microscopy images of fluorescently labeled, triple-functionalized GUVs produced by a droplet splitting microfluidic device. The fluorescence labels, 
Atto425-streptavidin, His-tagged GFP and NHS-Alexa647, were linked to NTA-Ni2+, biotin and NH2-conjugated lipids, respectively. (b and c) Schematic re-
presentations and microscopy images of sequential GUV functionalization with 50 nm gold nanoparticles (b) and antibodies (c). Right panels show a phase contrast 
image of GUVs linked to a gold nanoparticle (indicated by white arrows) and a fluorescence confocal image of GUVs functionalized with AlexaFluor488-linked Anti- 
CD3 IgG-immobilized via His-tagged ProteinG to NTA-Ni2+ lipids (c). Scale bars are 1 μm and 2 μm for (b) and (c), respectively. (d) Formation of an interaction area 
between anti-CD3-functionalized GUVs and CD3+ Jurkat T-cells after incubation for 24 h. Cell membranes were stained with WGA-AlexaFluor488 (top left image), 
GUVs were visualized by incorporation of LissRhod-PE fluorescent lipids (bottom left image) and nuclei in the merged image were stained with Hoechst 33342 
(middle). The arrow indicates the site of lipid clustering at the GUV-cell interface. The right image shows the respective bright field image. The scale bar is 6 μm. (e) 
Schematic representation of GUV decoration with integrin-specific RGD ligands to induce integrin-mediated attractive interactions at the GUV-cell interface. (f) 
Attraction analysis of RGD-functionalized GUVs incubated with different cell lines. The presented results are normalized to the attraction of naive GUVs, and shown 
as average value and SD from three technical replicates. Attraction of RGD-functionalized GUVs to Jurkat cells in suspension was assessed by flow cytometry. T-test 
with ** = p  <  0.001, *** = p  <  0.0001, n.s. not significant to the naïve vesicles treatment group in each graph. (g) Representative fluorescence confocal 
microscopy images of fluorescently labeled GUVs (LissRhod-PE) decorated with 2 mol% RGD ligands incubated with membrane-stained (WGA-AlexaFluor488) 
A431D cells. The scale bars are 60 μm. The areas surrounded by dashed borders are shown in greater magnification in the two images on the right. The accumulation 
of GUVs at the cell periphery and in the perinuclear region after incubation of 24 h is visible. See Table S1 for details on the lipid and buffer compositions. 
Fig. 4. Regulating attractive and repulsive GUV-cell interactions. (a) Schematic representation of the PEG-functionalized GUVs created to suppress non-specific 
charge-mediated GUV-cell interactions that interfere with ligand-specific GUV-cell interactions. (b) Heat map of the attraction analysis of PEG-functionalized GUVs 
that contain 50 mol% negatively charged lipids and are interfaced with Hela cells. (c) Representative bright field (first column) and fluorescence (second column) 
confocal microscopy images of A431 cells interfaced with naive, negatively charged GUVs (top row) or 50 mol% PEG1000-functionalized, negatively charged GUVs 
(bottom row). Naive GUVs are in direct contact with the cells while PEGylated GUVs accumulate in the intercellular space (merged image, third column) and form 
contact inhibition zones with the cells (the fourth column shows magnified images of the areas indicated by a black box in the merged images). White dotted lines 
indicate the periphery of cell groups deduced from the bright field image. Scale bars are 15 μm. See Table S1 for details on the lipid and buffer compositions. 
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bind to cells in a specific manner – e.g. poly-L-lysine (which mostly 
interacts based on electrostatic interaction), wheat germ agglutinin 
(WGA, which binds to the glycocalyx of cells), or HIV derived tat- 
peptide (an arginine-rich peptide which penetrates cell membranes 
mostly based on hydrophobic interactions) – showed high attraction to 
basically all cell types, as the nonspecific attractions were able to 
overcome the repulsive PEG-barrier in all cases. When targeting more 
specific receptors, e.g., bradykinin-specific G-protein-coupled receptors 
(abundantly expressed on epithelial cells) by functionalizing GUVs with 
the vasodilator bradykinin, we achieved specific attraction to en-
dothelial cells. In this case, specific attraction was increased up to 40% 
compared to other cell lines. Similar results were obtained when tar-
geting cadherin proteins by coating with recombinant cadherin or anti- 
cadherin antibodies. This comparison shows that the fine-tuning of 
specific attractive interactions and the use of PEG-based shielding of 
non-specific interactions is a well-suited strategy to target GUVs to 
specific cells4 
Finally, to assess whether our strategy for guided attraction is able 
to induce a cell-type specific uptake of GUVs in a more complex multi- 
cell type environment, we tested our GUV targeting approach in co- 
culture experiments. Towards this end, we chose astrocyte (Hs683) and 
neuronal (SH-SY5Y) model cell lines, as these cell types grow and in-
teract in great proximity in the mammalian brain. Moreover, achieving 
preferential GUV uptake by neurons is desirable when developing 
therapeutic strategies for neuroblastoma or neurodegenerative diseases. 
To test the guided attraction, we prepared GUVs composed of 20 mol% 
PEG750, 20 mol% EggPG, 58 mol% EggPC, 1 mol% LissRhod PE and 
1 mol% 18:1 DGS-NTA(Ni) lipids and functionalized these with the 
neuronal adhesion molecule His-tagged NrCAM (extracellular domain 
aa20 - 630) which binds to axonin-1 on neuronal membranes (Fig. 5c) 
[35]. Following 24 h of co-culturing the two cell types with GUVs, we 
performed confocal microscopy to analyze and quantify the interaction 
of the GUVs with each cell type from respective images (see Experi-
mental Section). The analysis revealed that neuronal cells contained up 
Fig. 5. Specific GUV-cell interactions. (a) Schematic representation of a PEGylated GUV biofunctionalized with receptor specific ligands to achieve specific attraction 
between GUVs and the respective receptor-expressing cell. (b) Attraction values of nonspecific (i.e., BSA, PLL, WGA and tat-peptide) and specific (i.e., anti-cadherin, 
recombinant cadherin and bradykinin) protein-biofunctionalized GUVs (via 5 mol% NHS lipids and 20 mol% PEG750) to human fibroblast BJ cells, neuroblastoma 
SH-SY5Y cells, endothelial MDCK cells, epithelial A431 cells, dexamethasone-treated epithelial transformed A431 cells and Hela cells. All values were normalized to 
the attraction of BSA-coupled GUVs. (c) Schematic representation of PEGylated GUVs biofunctionalized with NrCAM in a co-culture with astrocytes and neuronal 
cells, which lack and express the axonin-1 receptor, respectively. The bottom panel shows representative single plane confocal microscopy images of the co-culture of 
astrocytes (green) and neurons (blue) following 24 h of incubation with NrCAM-biofunctionalized, 20 mol% PEG750 conjugated GUVs. Hs683 astrocytes and SH- 
SY5Y neurons were stained with CellTracker Green and Blue, respectively. GUVs were visualized by incorporation of LissRhod-PE fluorescent lipids. The scale bar is 
50 μm. See Table S1 for details on the lipid and buffer compositions. 
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to 520% more GUVs compared to astrocytes, highlighting the im-
portance of fine-tuning attractive and repulsive interaction for targeted 
delivery of GUVs in a complex environment. 
2.5. Lysosomal escape of the GUV cargo for cytoplasmic delivery 
To investigate the mechanism of intracellular GUV uptake, we in-
cubated negatively charged GUVs with REF cells stained for endosomal 
vesicles and cytoplasm. Confocal microscopy of the respective cultures 
revealed that incorporated GUVs are surrounded by endosomal mem-
branes (Fig. 6a). This observation confirms that GUVs enter into the cells 
by endocytic pathways (e.g. micropinocytosis or phagocytosis), excluding 
other uptake mechanisms such as direct penetration or sole engulfment of 
the GUVs. However, following uptake, we observed a progressive loss of 
GUV fluorescence over time. After 24 h of incubation, fluorescence was 
found to co-localize with LysoTracker Green DND-26 stained organelles 
(Fig. 6b). This observation might be attributed to successive lysosomal 
degradation of the vesicles, a process frequently observed for SUV-based 
delivery methods. Yet because many pharmacological compounds target 
cytoplasmic components, efficient lysosomal escape mechanisms that 
allow for the release of GUV cargo into the cell and avoid lysosomal 
degradation are a pivotal requirement for such applications [36,37]. 
To circumvent lysosomal degradation, we assessed three independent 
lysosomal escape mechanisms, all of which are based on the sudden 
decrease in pH occurring during endosome-lysosome fusion: 1) 
Lysosomal escape via a proton sponge mechanism based on the in-
corporation of high molecular weight poly-ethylene-imine (PEI) into the 
GUVs [38]; 2) Lysosomal escape via intra-lysosomal membrane fusion 
and pore formation by attachment of the pH-sensitive GALA peptide onto 
the GUV surface [39]; 3) Lysosomal escape via intra-lysosomal fusion by 
incorporation of the pH-sensitive lipid DOBAQ into the GUV membrane 
[40]. We exemplarily assessed the retention, degradation and release of 
GUV cargo by loading the GUVs with the membrane impermeable dye 
HPTS and observing its intracellular fluorescence distribution after 24 h 
of incubation of the respective GUVs with A431D cells (Fig. 6c). In the 
cases of PEI-loaded and GALA-coupled GUVs, HPTS fluorescence was 
exclusively detected in punctuated form, co-localizing with fluorescence 
originating from the GUVs inside the cells. This indicates HPTS retention 
inside the GUVs and, therefore, endosomal or lysosomal entrapment, 
suggesting unsuccessful cytoplasmic cargo release. However, in the case 
of GUVs containing 60 mol% DOBAQ, HPTS fluorescence was found 
distributed throughout the entire cell body, thus proving successful re-
lease of HPTS from the GUVs into the cytoplasm. Indeed, DOBAQ-con-
taining GUVs show polarity switching of their ζ-potential at low pH, as 
assessed by dynamic light scattering (Fig. S9). 
The dynamics of endocytosis and lysosomal activity can sig-
nificantly vary between transformed and untransformed cells, therefore 
we aimed to also test our approach on primary cells [41,42]. For these 
Fig. 6. Lysosomal degradation of the vesicles and the assessment of the mechanisms for lysosomal escape to allow intracellular GUV cargo release. (a) Representative 
fluorescence confocal microscopy images of REF cells loaded with endosomal entrapped, negatively charged GUVs. Nuclei (top left image) were stained with Hoechst 
33342, endosomes (top center image) were labeled by staining with WGA-AlexaFluor488 for 24 h, GUVs (bottom left image) were visualized by incorporation of 
LissRhod-PE fluorescent lipids, and cytoplasm (bottom center image) was stained using CellTracker Green. The merged image (right image) shows that GUVs reside 
within the cytoplasm and are entrapped in endosomal vesicles. The scale bar is 10 μm. (b) Representative fluorescence microscopy images of REF cells showing co- 
localization of GUVs with lysosomal compartments after 24 h of incubation. Lysosomes (left panel) were stained with LysoTracker Green and GUVs (center panel) 
were visualized by incorporating LissRhod-PE fluorescent lipids. The right panel shows bright field images. The scale bar is 10 μm. (c) Representative fluorescence 
confocal microscopy images of the assessment of PEI-, GALA peptide- and DOBAQ-mediated lysosomal escape for HPTS(green)-loaded GUVs (yellow) incubated with 
REF cells for 24 h. The scale bar is 50 μm. (d) Representative fluorescence confocal microscopy and bright field images of primary mouse hippocampal neurons (right 
panel) incubated with GUVs (left panel, visualized by incorporation of 1 mol% LissRhod PE lipids) loaded with HPTS (center panel) and containing 60 mol% of the 
pH-sensitive lipid DOBAQ. The scale bar is 30 μm. See Table S1 for details on the lipid and buffer compositions. 
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experiments, we used in vitro cultured primary hippocampal neurons 
[43], cells that represent an important target in many therapeutic 
procedures treating neurodegeneration or neuronal tumors. When in-
terfaced with HPTS-loaded and DOBAQ-containing negatively charged 
GUVs, we observed extensive uptake of the GUVs into the neurons after 
24 h of incubation (Fig. 6d). In order to enhance their attraction to the 
sialic acid-containing glycocalyx, the GUVs were functionalized with 
WGA. Their accumulation in the perinuclear region suggests in-
corporation into the cell's intracellular trafficking machinery. Im-
portantly, we observed widespread distribution of HPTS fluorescence 
within the neuronal soma and in the dendrites. This observation proves 
that DOBAQ-based lysosomal escape of GUV cargo is functional and 
compatible with primary cells. 
2.6. Delivery of very large complex cargo 
To ultimately assess the cargo capacity of GUVs formed by micro-
fluidics for novel therapeutic approaches, we performed microfluidic 
loading of purified virions formed by baculovirus (BV). BV is a non- 
human, arthropod specific enveloped virus comprising a double-stranded 
DNA genome ~140 kb in size, characterized by a flexible capsid which 
can accommodate very large (exceeding 100 kb) additional heterologous 
DNA insertions. The membrane envelope of BV can be engineered to 
alter the tropism of this originally insect-cell specific virus, converting BV 
into a non-replicative, non-integrating tool for delivering complex DNA 
circuitry into mammalian cells, tissues and organisms [44,45]. Due to its 
very large DNA capacity, combined with the ease of manufacture and 
engineering, BV is emerging as a promising tool for genome engineering 
approaches in gene and cell therapy, potentially as a replacement tech-
nology for current viral vector systems (adenovirus, adeno-associated 
virus, lentivirus) [46]. We reasoned that the potential of BV could be 
maximized, ultimately for in vivo applications, by utilizing GUVs to 
transport and protect defined ensembles of BVs to target cells and tissues 
of choice. By using our microfluidics approach, we achieved successful 
assembly and release of BV-loaded GUVs (Fig. 7a). Next, the BV-loaded 
DOBAQ-containing GUVs were incubated with REF cells for 24 h. By 
confocal microscopy we observed intracellular uptake of the GUVs, as 
well as release of the BV (stained by Hoechst 33342, see Experimental 
Section) into the cell cytoplasm (Fig. 7b). This was accompanied by the 
expression of mitochondrial targeted dsRed protein encoded by the BVs, 
indicating successful GUV based transduction of mammalian cells with 
BV carrier GUV. Moreover, quantification of the dsRed fluorescence in 
cultures treated with GUV-entrapped BVs and soluble BVs showed that 
GUV-based intracellular delivery of the virions can significantly augment 
the expression of exogenious BV-encoded genes (Fig. S10). These results 
highlight the advantages of GUV-based drug delivery towards more ef-
ficient drug administration of very large complex cargo, here entire BVs, 
that would not be possible by conventional SUV-based delivery. 
3. Summary and outlook 
In this study, we developed a high-throughput droplet-based micro-
fluidic production pipeline for producing large amounts of well-defined 
carrier-GUVs (d ≈ 2 μm) for drug delivery purposes. The presented 
technology is based on three subsequent steps: 1) well-controlled assembly 
of dsGUVs; 2) dsGUV mechanical splitting; and 3) the release of fully 
equipped GUVs into a physiological environment. This sequential as-
sembly approach allows for highly efficient cargo loading and un-
precedented control over the biological and physicochemical properties of 
the GUVs membranes. The ability to control GUV properties – specifically 
control over size, cargo, robustness during handling as well as specificity 
and strength of interactions – in such a precise manner has allowed us to 
perform a systematic assessment of key factors that dominate GUV-cell 
interactions and to explore concepts for targeted GUV delivery. We con-
ceptually show how charge-driven as well as specific ligand-receptor- 
based attractive interaction between GUVs and cells can be utilized for 
regulating uptake. Moreover, we present a systematic evaluation of how 
PEG decoration of GUVs, which creates repulsive interactions can be 
employed to decrease nonspecific, electrostatic interactions and boost 
targeting specificity. We further describe a simple but efficient cytoplasmic 
release strategy for GUV cargos, based on the pH-sensitive lipid DOBAQ. 
The exquisite control over the GUV composition as well as the described 
GUV functionalization strategies allow for the construction of GUVs with 
an excessive functional diversity and high targeting specificity. 
Our results with BV-loaded GUVs compellingly demonstrate that 
our approach could be applied in the future for transporting and deli-
vering very large, complex cargo to cells and tissues of choice. Freights 
could include ensembles of viruses with multiple genome engineering 
modalities, or drug releasing porous microparticles, unprecedented 
quantities in vivo imaging probes, DNA origami robots and other bio-
logical and synthetic nanodevices or combinations thereof. In this case, 
the GUV shell could not only allow for targeted transport, but also 
prevent cargo degradation inside the GUV lumen. Moreover, by func-
tionalizing the GUV surface, potentially immunogenic cargo could be 
shielded from immune reactions. Once the GUV arrived at its destina-
tion, the cargo would then be intracellularly discharged via the lyso-
somal escape mechanism. The mechanical stability of droplet-splitted 
GUVs could in future be further increased by their coating with stabi-
lizing polymers and/or sugars. Such mechanically more robust GUVs, 
Fig. 7. GUV-based delivery of heavy duty and complex cargo. (a) Representative 
bright field (left panel) and corresponding confocal microscopy (right panel) 
images of a BV-loaded GUV. The scale bar is 2 μm. (b) Maximal z-projection of 
fluorescence confocal microscopy images of REF cells (nuclei stained with 
Hoechst 33342, top left image) that were incubated for 24 h with baculoviruses 
(bottom left image, visualized by oversaturation of the Hoechst 33342 channel) 
that had been loaded into DOBAQ-containing GUVs (top right image). Note the 
visible expression of mitochondria-targeted dsRed (bottom right image). The 
scale bar is 25 μm. See Table S1 for details on the lipid and buffer compositions. 
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could then pave the way for long lasting blood circulation or other in 
vivo application which require high mechanical stability. This study, 
characterizing GUV-cell interactions and GUV guidance, lays the 
foundation for such highly promising future applications. Moreover, 
our investigation of GUV-cell interactions will prove useful for bottom- 
up synthetic biology approaches, aiming to create novel systems in 
between living and synthetic cells. Here, interaction within hybrid tis-
sues and therefore the micro- and mesoscale architecture of these, could 
be controlled using the concepts presented in this study. 
4. Experimental Section 
4.1. Materials 
EggPG L-α-phosphatidylglycerol (Egg, Chicken), EggPC L-α-phosphati-
dylcholine (Egg, Chicken), 18:1 DOPG 1,2-dioleoyl-sn-glycero-3-phospho- 
(1′-rac-glycerol), 18:1 DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholestero-
line, 18:1 DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, LissRhod 
PE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine 
B sulfonyl), 18:1 DGS-NTA(Ni) 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1- 
carboxypentyl)iminodiacetic acid)succinyl] (nickel salt), 18:1 DOTAP 1,2- 




PEG350 PE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy 
(polyethylene glycol)-350], 18:1 PEG750 PE 1,2-dioleoyl-sn-glycero-3- 
phosphoethanolamine-N-[methoxy(polyethylene glycol)-750], 18:1 
PEG1000 PE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy 
(polyethylene glycol)-1000], and extrude set with 50 nm pore size poly-
carbonate filter membranes were purchased from Avanti Polar Lipids, USA. 
All lipids were stored in chloroform at −20 °C and used without further 
purification. DyLight 405 NHS Ester, AlexaFluor 647-NHS, Anti CD3 (16- 
0038-81), Anti CD3-Alexa488 (53-0037-42), Hydroxypyrene-1,3,6-tri-
sulfonic acid trisodium salt (HPTS), Hoechst 33342, CellTracker Blue CMAC 
dye, CellTracker Green CMFDA dye, LysoTracker Green DND-26 dye, wheat 
germ agglutinin (WGA)-AlexaFluor conjugates, Dulbecco's Modified Eagle 
Medium (DMEM) high Glucose, 1:1 DMEM:F12, RPIM-1640, FluoroBrite 
DMEM (high glucose), heat inactivated fetal bovine serum, penicillin- 
streptomycin (10,000 U/mL), GlutaMax Supplement, L-Glutamine 
(200 mM), trypsin-EDTA (0.05%) with phenol red, phosphate buffered 
saline, basic fibroblast growth factor (aa 10–155), Epithermal growth factor, 
AlexaFluor405 dye and custom synthesized GALA peptide (EAALAE ALA-
EALAEHLAEALAEALEALA) were purchased from Thermo Fischer Scientific, 
Germany. NHS Palmitic acid N-hydroxysuccinimide ester, 97% L-cysteine, 
50 nm Au nanoparticles, heat-inactivated horse serum, lectin (Wheat Germ 
Agglutinin), 1H,1H,2H,2H-Perfluoro-1-octanol (PFO) de-emulsifier, brady-
kinin, polyethylenimine (branched, Mw ~25,000), Atto425-Biotin, human 
Interleukin 2, recombinant insulin, fibronectin from bovine plasma, poly-L- 
lysine and DOBAQ N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy) 
propan-1-aminium were purchased from Sigma Aldrich, Germany. 
Polydimethylsiloxan (PDMS) Sylgard 184 was purchased from Dow 
Corning, USA. Protein G His-tag was purchased from BioVision, USA. 
Bovine albumin fraction V (BSA) was purchased from Carl Roth, Germany. 
His-tagged NrCAM 8425-NR-050 and human recombinant cadherin were 
purchased from R&D Systems, USA. Fluoresbrite YG Microspheres 1.00 μm 
were purchased from Polysciences Europe, Germany. Perfluoropolyether- 
polyethylene glycol (PFPE-PEG) block-copolymer fluorosurfactant was 
purchased from Ran Biotechnologies, USA. Anti-VE-Cadherin and anti- 
alpha4-integrin (CD49d) antibodies were purchased from Santa Cruz (Sc- 
28644) and Millipore (MAB1383). Recombinant human CD95L was pur-
chased from BioLegend, USA. A431, Hela, Hs386, SH-SY5Y and Jurkat cell 
lines were obtained from ATCC, USA. REF52 cell lines [47] were a generous 
gift from Prof. Benjamin Geiger (Weizmann Institute, Rechovot). PC12 cells 
were a generous gift from Amin Rustom (Institute for Neurobiology, Hei-
delberg). Primary mouse hippocampal neurons were obtained from the 
Institute of Neurobiology, Interdisciplinary Center for Neurosciences in 
Heidelberg, Germany. Purified baculovirus specimens were obtained from 
Martin Pelosse (Commissariat à l'énergie atomique et aux énergies alter-
natives, CEA Grenoble, France). Tat-HIV-GFP peptides were a generous gift 
from Rüdiger Arnold (Life Science Lab, German Cancer Research Center). 
4.2. Microfluidic-based GUV production 
For the production of dsGUVs, SUV solution using the lipid com-
positions given in Table S1 were mixed as described previously [22,23]. 
Briefly, lipids dissolved in chloroform were mixed at respective ratios in 
glass vials and dried under a gentle nitrogen stream. The dried lipid 
films were rehydrated to a final lipid concentration of 3 mM in pro-
duction buffers given in Table S1 for 30 min. Subsequently, the solution 
was shaken for 5 min at min. 600 rpm. The resulting liposome solution 
was extruded at least 9 times through a 50 nm pore size polycarbonate 
filter. SUVs solutions were stored at 4 °C for up to 3 days or used for 
dsGUV production immediately. 
Droplet-based microfluidic mechanical splitting devices were fabricated 
from PDMS. The devices were produced as previously described using 
photo- and soft-lithography methods [48]. Flow rates were controlled by an 
Elveflow OB1 MK3-microfluidic flow control system. If not stated other-
wise, for the formation of GUVs within microfluidic droplets the SUV so-
lutions were diluted to a final lipid concentration of 1.5 mM. For droplet 
formation, the SUV solutions were introduced into the aqueous channel of 
the microfluidic devices. Negatively charged GUVs were formed using 
1.25 mM PFPE(7000 g/mol)-PEG(1500 g/mol)-PFPE(7000 gr/mole) triblock surfac-
tant dissolved in FC-40. Positively charged GUVs were formed using 0.5% 
RAN Biotechnologies PEG-based fluorosurfactant diluted in FC-40. For 
formation of GUVs containing DOBAQ lipids for lysosomal escape, 
1.25 mM PFPE(2500 g/mol)-PEG(600 g/mol)-PFPE(2500 g/mol) triblock surfactant 
diluted in FC-40 was used. Note that the addition of certain amounts of 
PFPE-COOH might be neccessary due to batch-to-batch variations in the 
surfactant purity. An aqueous to oil phase ratio of approximately 1:4 was 
used for all droplet productions. Droplets were formed at the flow-focusing 
junction of the splitting devices and collected from the outlet of the mi-
crofluidic chip into a microtube. Following collection, dsGUV were allowed 
to equilibrate for a minimum of 2 h at 4 °C before release. 
For the release of dsGUVs from the oil phase and the stabilizing 
polymer shell, the excess oil phase was removed from the microtube. The 
droplet layer was mixed in a volume ratio of 1:1:1 (aq. production buffer: 
aq. Release buffer (see Table S1): destabilizing PFO). Following 30 min of 
equilibration, the GUV-containing aqueous phase was transferred into a 
2 mL microtube. Release buffer was added to a total volume of 2 mL and 
GUVs were centrifuged at > 10.000 g for 15 min. The supernatant was 
discarded and the pellet was suspended to obtain the desired concentration. 
4.3. Dynamic light scattering 
Zeta potentials of GUVs and SUVs were measured with a Malvern 
Zetasizer Nano ZS system at a total lipid concentration of 15 μM in PBS. 
Equilibration time was set to 600 s at 25 °C, followed by three repeat 
measurements for each sample at a scattering angle of 173° using the 
built-in automatic run-number selection. The material refractive index 
was set to 1.42 [49] and solvent properties to η = 0.8882, n = 1.33 and 
ε = 79.0. For GUV zeta-potential measurements, equilibration time and 
number of individual measurements were set to 120 s and 2 repeats, 
respectively. The zeta-potential of DOBAQ-containing GUVs was as-
sessed by diluting GUVs to a final lipid concentration of 15 μM in PBS 
adjusted to the desired pH by adding 4 N NaOH or 10% HCl. All zeta- 
potential measurements were performed at least in duplicates. 
4.4. Assessment of droplet homogeneity 
To assess transmission heterogeneity of intraluminal droplet con-
tents, w/o droplets were produced at a flow-focusing junction of either 
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a droplet splitting device or a simple droplet production device. A PBS 
aqueous phase containing 10 mM MgCl2, 1 mM AlexaFluor405, 1 μM 
His-tagged GFP, 1.08 × 109 particles/mL Fluoresbrite YG Microspheres 
(D = 1.00 μm) was used. Droplets were collected and mean droplet 
fluorescence intensity for all fluorophores was measured from single 
plane fluorescence confocal images using global thresholding segmen-
tation and the ImageJ particle analyzer. 
4.5. Quantitative mass spectrometry 
For quantitative mass spectrometry analysis of SUV and GUV lipid 
content, GUVs were produced from the SUVs composed of 33 mol% 
DOTAP, 33 mol% DOPE, 33 mol% DOPC, 1 mol% LissRhod PE with 0.5% 
RAN Biotechnologies PEG-based fluorosurfactant diluted in FC-40. Relative 
quantitative mass spectrometry was performed using a Sciex QTRAP 4500 
mass spectrometer hyphenated with a Shimadzu Nexera HPLC system. The 
instruments were controlled using Sciex Analyst 1.7 software. Samples were 
sonicated for 3 min and diluted 1 to 1000 in LCMS grade MeOH and sub-
sequent fractionation was performed using a Supelco Titan C18 column 
(0.21 × 10 cm, 1.9 μ) operated at 45 °C. The isocratic method featured a 
flow rate of 0.5 mL/min using a 10 mM NH4Ac solution in 98% MeOH aq. 
The MS experiments were performed in MRM mode using the following 
instrument settings: curtain gas 35 psi, ionization voltage 5500 V, nebulizer 
gas 30 psi, heater gas 60 psi, heater temperature 180 °C and a CAD gas set to 
















DOPE 744.498 603.500 110 91 33 16 
DOTAP 662.528 603.500 50 166 41 20 
DOPC 786.528 184.000 50 161 39 14 
LissRhod 1301.605 682.000 110 40 67 24 
MS experiments were performed in triplicates. Data analysis was performed 
using Sciex Analyst 1.7 and MultiQuant 3.0.2 software. Calculated concentra-
tions were normalized using a SUV sample containing DOPE: DOTAP: DOPC: 
Liss Rhod PE with the following initial lipid ratios 33 : 33: 33 : 1.  
4.6. Quantification of release efficiency and stability 
Release efficiency and GUV mechanical stability after agitation were 
assessed by manually counting dsGUV and released GUVs with a 
Neubauer chamber mounted on a fluorescence microscope. The total 
lipid concentration of released and cleaned GUVs was quantified by 
measuring GUV solution fluorescence (Fig. S9). Respective fluorescence 
was normalized to a standard SUV dilution curve (fitted to one phase 
exponential decay) of known concentration and with equal ratios of 
fluorescently labeled lipids. For incubation of GUVs with cell lines total 
lipid concentrations between 1.5 μM and 50 μM were used. 
4.7. Cell culture 
REF52 cells, MDCK cells, A431 and A431D cells [50], Hela cells and 
Hs386 cells were cultured in Dulbecco's Modified Eagle Medium supple-
mented with 4.5 g/L glucose, 1% L-glutamine, 1% penicillin/streptomycin 
and 10% fetal bovine serum. SH-SY5Y cells were cultured in a 1:1 mixture 
of F12:DMEM supplemented with 1% L-glutamine, 1% penicillin/strepto-
mycin and 10% fetal bovine serum. Jurkat cells were cultured in RPMI- 
1640 medium supplemented with 1% penicillin/streptomycin and 10% 
fetal bovine serum. PC12 were cultured in RPIM-1640 medium supple-
mented with 1% L-glutamine, 1% penicillin/streptomycin 5% fetal bovine 
serum and 10% heat-inactivated horse serum. Cell cultures were routinely 
cultured at 37 °C and 5% CO2 atmosphere and passaged at ~80% con-
fluency based on 0.05% trypsin/EDTA treatment. Jurkat cells were pas-
saged by adding 1 mL of Jurkat culture to 4 mL of fresh culture medium. 
4.8. Cell staining 
Live cells were stained with Hoechst 33342 at a final concentration 
of 5 μg/mL to visualize cell nuclei. Cytoplasms were stained with 
CellTracker Blue CMAC dye and CellTracker Green CMFDA dye fol-
lowing the manufacturer's instructions. Lysosomes were stained with 
LysoTracker Green DND-26 dye following the manufacturer's instruc-
tions. Cell membranes were stained with wheat germ agglutinin (WGA)- 
AlexaFluor conjugates. Membranes were stained by adding WGA con-
jugates to a final concentration of 50 μg/mL to cells grown in fully 
supplemented growth medium for 10 min at room temperature. To 
reduce endocytotic dye uptake, stained cells were handled for imaging 
at room temperature. WGA was previously also used to stain for en-
dosomal and Golgi-associated vesicles [51]. To stain endosomal GUV 
uptake, cells incubated with GUVs were incubated with a final con-
centration of 5 μg/mL WGA-AlexaFluor conjugates for 24 h. 
4.9. Confocal microscopy and live cell imaging 
For fluorescence confocal microscopy observations, cell lines were 
cultured in 8-well Nunc LabTeK glass bottom culture slides filled with 
minimum 400 μL of culture medium. Confocal microscopy was performed 
with a laser scanning microscope LSM 800 (Carl Zeiss AG). Images were 
acquired with a 20x (Objective Plan‐Apochromat 20x/0.8 M27, Carl Zeiss 
AG) and a 63x immersion oil objective (Plan‐Apochromat 63x/1.40 Oil 
DIC, Carl Zeiss AG). Images were analyzed with ImageJ (NIH). Adjustments 
of image brightness and contrast or background corrections were per-
formed always on the whole image and special care was taken not to ob-
scure or eliminate any information from the original image. For images 
with speckled noise signals, 2 pixel median filters were applied. For cell 
fixation prior to confocal microscopy analysis, cell cultures were washed 
twice with PBS and subsequently fixed with 2–4% PFA for a minimum of 
20 min. For time-lapse live cell imaging a Leica DMi8 inverted fluorescent 
microscope equipped with a sCMOS camera and 10x HC PL Fluotar (NA 
0.32, PH1) objective was used. Cells were cultured in 8-well Nunc LabTeK 
glass bottom culture slides in FluoroBrite DMEM (high glucose) medium 
supplemented with GlutaMAX, 10% FBS and 1% Pen/Strep. 
4.10. Transmission electron microscopy 
REF cells incubated for 16 h with GUVs were fixed in 2.5% glutar-
aldehyde dissolved in a 0.1 M Na3PO4 solution for 30 min at room 
temperature. Cells were further fixed in 0.4% uranyl acetate overnight. 
Fixed cells were subsequently dehydrated with a 50%, 60%, 70%, 80%, 
90%, and 100% ethanol series and embedded in resin over night at 60 °C. 
85 nm ultrathin sections were prepared and contrasted with lead acetate 
or osmium tetroxide. A Zeiss EM 10 CR transmission electron microscope 
was used for imaging. If necessary, image contrast, brightness and 
sharpness were adjusted using the built-in ImageJ plug-ins. 
4.11. Flow cytometry 
As Jurkat cells are a leukemia-derived cell line which grows in 
suspension, the attraction assay developed for adherent cells cannot be 
applied to them. To also evaluate the attraction of GUVs to such sus-
pension cells, a flow cytometry-based assessment was performed. For 
flow cytometry analysis of the attraction between RGD-functionalized 
GUVs and Jurkat cells, Rhodamine B-GUVs with varying RGD density 
(see Table S1) were incubated with Jurkat cells for 24 h. Cells were 
subsequently centrifuged for 5 min at 250 g and the supernatant, which 
contained GUVs that were unbound or had not been taken up by cells, 
was discarded. Cells were resuspended in fresh culture medium and for 
each condition GUV fluorescence within the cells was quantified with a 
BD LSRFortessa Cell Analyzer (BD Bioscience) using the blue laser line 
in the PE channel (λem max = 575). A gate was then set to discriminate 
between Jurkat cells, debris and possible clumps based on the 
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acquisition of scattered parameters. Subsequently, singlet cells were 
extracted from the aforementioned Jurkat population. Lastly, based on 
this gating strategy, fluorescence intensity associated with the cells’ 
periphery was recorded and quantified. 
4.12. Attraction assay 
Attraction assays were performed as outlined in Fig. S3. Cells were 
seeded in triplicates in 100 μL of their corresponding growth medium to 
form a confluent monolayer after 24 h of incubation in 96 flat-bottom 
well-plates. GUV (labeled with LissRhod PE lipids) solutions were added 
to a final lipid concentration of 1.5 μM and incubated for 24 h. Fluor-
escence in each well was measured using an Infinite M200 TECAN plate 
reader controlled by TECAN iControl software with an in-built gain op-
timization and excitation/emission setting adjusted to 550/585 nm. 
Subsequently, wells were washed 3x with 100 µL PBS using a multi-
channel pipette and residual fluorescence was measured again. Fluores-
cence intensity after washing was normalized to the intensity before 
washing in order to account for any variation in sample preparation. All 
samples were measured in triplicates at 4 individual positions per well in 
order to account for variations in cell monolayer density. For comparing 
the specific attraction of biofunctionalized GUVs to specific cell lines, all 
attraction values were normalized to the attraction of BSA functionalized 
GUVs and the respective cell line in order to reference all attraction 
values for each cell type to a common moderately non-reactive protein. 
A total lipid concentration of 3 μM of anti-CD3 functionalized GUVs 
and Jurkat cells were incubated for 24 h in order to perform fluores-
cence confocal microscopy observations of the attraction and formation 
of contact sides. Prior to imaging, cells were stained with Hoechst 
33342 and WGA-AlexaFluor 647 as described above. 
4.13. Quantification of preferential GUV uptake in co-culture 
To quantify preferential GUV uptake in SH-SY5Y/Hs683 co-culture 
experiments, SH-SY5Y and Hs683 cell were separately stained with 
CellTracker Blue CMAC and CellTracker Green CMFDA, respectively. 
Cells were co-seeded at a 10:1 SH-SY5Y:Hs683 ratio in a 1:1 mixture of 
F12:DMEM supplemented with 1% L-glutamine, 1% penicillin/strep-
tomycin and 10% fetal bovine serum together with GUVs composed of 
20 mol% PEG750 PE, 20 mol% EggPG, 58 mol% EggPC, 1 mol% 
LissRhod PE and 1 mol% palmitic acid-NHS coupled with 1.5 μM His- 
tagged recombinant NrCAM for 24 h. Cell cultures were subsequently 
washed 3x with PBS and fixed for 20 min with 4% PFA followed by 
fluorescence confocal microscopy analysis with appropriate laser ex-
citation. The total area of SH-SY5Y and Hs683 cells in a field of view 
was calculated from single plane confocal images. The total number of 
GUVs in respective areas was determined by global threshold segmen-
tation and subsequently normalized to the total cell area. E.g., total area 
of SH-SY5Y and Hs683 cells (shown in Fig. 5c) is 20083.37 μm [2] and 
40741.67 μm [2], respectively. They contain 1491 (= 0.0742 GUVs/ 
μm [2]) and 578 (= 0.0141GUV/μm [2]) GUVs, respectively, which 
corresponds to an increase of 523% in the case of SH-SY5Y cells. 
4.14. Encapsulation of baculoviruses 
For intracellular delivery of baculoviruses (BVs), BVs were produced 
using the MultiBac baculovirus/insect cell system [52]. Solutions con-
taining purified BVs were mixed in a 1:100 ratio with the SUV solution. 
Importantly, for dsGUV production, PBS with 60 mM MgCl2 was used, 
as lower manganese concentrations inhibited dsGUV formation and 
release rates. Released and cleaned GUVs containing BVs were then 
incubated with REF cells for 24 h and subsequently stained with 8 μg/ 
mL Hoechst33342. Expression of BV encoded mito-dsRed and BV lo-
calization was assessed my fluorescence confocal microscopy. For vi-
sualizing intracellular BV, staining of BV-DNA was imaged by over-
exposing the Hoechst33342 channel. 
4.15. GUV biofunctionalization and PEGylation 
GUV biofunctionalization was solely performed on released GUVs. If 
not stated otherwise, GUV functionalization was carried out in PBS buffer 
and in the dark on a horizontal shaker at room temperature. After 
functionalization, GUVs were centrifuged at > 10.000 g for a minimum 
of 15 min and resuspended in PBS. For NHS-based coupling reactions, 
GUVs were kept whenever possible at 4 °C and released from droplets not 
later than 1 h after production. NHS coupling reactions were performed 
over a minimum of 3 h. For NHS and NTA-based biofuntionalizations, 
respective proteins and peptide were added in 2–5 fold excess to total 
functionalized lipids as calculated from the total lipid concentration. For 
example, if fluorescence quantification showed a total lipid concentra-
tion of 150 μM (corresponding to an approx. Release efficiency of 10%) 
and GUVs were produced from SUVs with 1 mol% palmitic acid NHS 
lipids, then a minimum of 1.5 μM of the protein to be coupled was added 
(about 50% of the NHS-coupled lipids would reside within the inner 
membrane leaflet and not be accessible for coupling). In the case of the 
WGA coupling, lectin coupled to GUVs was employed at a 10 times lower 
molar concentration than the presented 5 mol% NHS ligand. GUV bio-
functionalization with RGD peptides was performed by introducing a 
desired amount of DSPE-RGD into the lipid mixture for SUV production. 
For the sequential functionalization of GUVs with gold nanoparticles 
(AuNP), GUVs containing 1 mol% NHS were incubated with 3 μM L- 
cysteine for 6 h. Subsequently, 50 nm Au nanoparticles were added to a 
final concentration of 10 μg/mL and the mixture was shaken at 300 rpm 
overnight. The functionalization of GUVs with IgG antibodies was per-
formed by incubating 3 μM His-tag Protein G with GUVs containing 
1 mol% 18:1 DGS-NTA(Ni) lipids for 1 h. Subsequently, a final con-
centration of 3 μM of respective IgG dissolved in 1% BSA was added to 
the mixture and incubated for 1 h. In order to avoid cross reactions 
whenever multiple functionalizations based on different coupling reac-
tions were performed (as in the case of triple functionalization), proteins 
to be coupled via NHS were incubated with the GUVs first before per-
forming other reactions like biotin-streptavidin coupling, for example. 
PEGylation of GUVs with poly-ethylene-glycol polymers was per-
formed by introducing a desired amount of PEG350 PE, PEG750 PE or 
PEG1000 PE into the lipid mixture for SUV production. 
4.16. Lysosomal escape mechanisms 
For all tested approaches, dsGUVs were produced in PBS with 10 mM 
MgCl2 and 50 mM 8-Hydroxypyrene-1,3,6-trisulfonic acid trisodium salt 
using 1.25 mM triblock PFPE-PEG-PFPE 2500-600-2500 surfactant dis-
solved in FC-40. Released GUVs were cleaned by centrifugation and in-
cubated with REF cells for 24 h. Intracellular HPTS fluorescence distribution 
was subsequently assessed by fluorescence confocal microscopy. Imaging 
parameters were kept constant when comparing the different approaches. 
Poly-ethylene-imine (PEI): For lysosomal escape analysis using the 
PEI proton sponge mechanism, GUVs composed of 20 mol% EggPG, 
79 mol% EggPC and 1 mol% LissRhod PE were loaded with 44 μg/mL 
poly-ethylene-imine during droplet production. 
GALA peptide: For lysosomal escape analysis using GALA-mediated 
intralysosomal fusion, GUVs composed of 1 mol% LissRhod PE, 1 mol% 
palmitic acid NHS, 20 mol% EggPG and 79 mol% EggPC were released 
and then coupled with 1.5 μM GALA peptide (EAALAE ALAEALAEHL-
AEALAEALEALA) in PBS. 
DOBAQ: For lysosomal escape analysis using DOBAQ-mediated in-
tralysosomal fusion, GUVs composed of 1 mol% LissRhod PE, 60 mol% 
DOBAQ, 20 mol% EggPG and 19 mol% EggPC were produced with PBS 
containing additional 50 mM HEPES for pH stabilization. 
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